Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1981 1
1982 2
1983 1
1984 1
1985 3
1986 2
1987 9
1988 6
1989 4
1990 9
1991 3
1992 13
1993 18
1994 18
1995 11
1996 24
1997 18
1998 23
1999 19
2000 40
2001 36
2002 54
2003 45
2004 75
2005 63
2006 59
2007 84
2008 68
2009 71
2010 76
2011 65
2012 61
2013 94
2014 72
2015 67
2016 65
2017 72
2018 68
2019 64
2020 83
2021 79
Text availability
Article attribute
Article type
Publication date

Search Results

1,511 results
Results by year
Filters applied: . Clear all
Page 1
Pharmacological Management of Dementia with Lewy Bodies.
Hershey LA, Coleman-Jackson R. Hershey LA, et al. Drugs Aging. 2019 Apr;36(4):309-319. doi: 10.1007/s40266-018-00636-7. Drugs Aging. 2019. PMID: 30680679 Free PMC article. Review.
DLB is the third most common of all the neurodegenerative diseases behind both Alzheimer's disease and Parkinson's disease (PD). The median age of onset for DLB (76.3 years) is younger than that seen in PD dementia (81.4 years). New pathological studies have shown t …
DLB is the third most common of all the neurodegenerative diseases behind both Alzheimer's disease and Parkinson's disease (PD …
Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update.
Gonzalez-Latapi P, Bhowmick SS, Saranza G, Fox SH. Gonzalez-Latapi P, et al. CNS Drugs. 2020 Oct;34(10):1025-1044. doi: 10.1007/s40263-020-00754-0. CNS Drugs. 2020. PMID: 32785890 Review.
Targeting these non-dopaminergic receptors remains a focus of ongoing research to improve Parkinson's disease (PD) motor symptoms, without the potential side effects of dopamine replacement therapy. ...The largest area of development in non-dopaminergic targets has been fo …
Targeting these non-dopaminergic receptors remains a focus of ongoing research to improve Parkinson's disease (PD) motor symptoms, wi …
Zonisamide.
Leppik IE. Leppik IE. Epilepsia. 1999;40 Suppl 5:S23-9. doi: 10.1111/j.1528-1157.1999.tb00916.x. Epilepsia. 1999. PMID: 10530691 Free article. Review.
Zonisamide (ZNS) is a broad-spectrum antiepileptic drug in both animal models of epilepsy and patients with epilepsy. ...
Zonisamide (ZNS) is a broad-spectrum antiepileptic drug in both animal models of epilepsy and patients with epilepsy. ...
Zonisamide Therapy for Patients With Paroxysmal Kinesigenic Dyskinesia.
Matsuura R, Hamano SI, Hiwatari E, Ikemoto S, Hirata Y, Koichihara R, Kikuchi K. Matsuura R, et al. Pediatr Neurol. 2020 Oct;111:23-26. doi: 10.1016/j.pediatrneurol.2020.06.017. Epub 2020 Jun 30. Pediatr Neurol. 2020. PMID: 32951651
METHODS: We analyzed zonisamide therapy in 17 patients with PKD at Saitama Children's Medical Center between November 1994 and April 2020. We collected information regarding family history, previous history, age at onset, age at zonisamide commencement, dyski …
METHODS: We analyzed zonisamide therapy in 17 patients with PKD at Saitama Children's Medical Center between November 1994 and …
Zonisamide for essential tremor.
Bruno E, Nicoletti A, Filippini G, Quattrocchi G, Colosimo C, Zappia M. Bruno E, et al. Cochrane Database Syst Rev. 2017 Aug 24;8(8):CD009684. doi: 10.1002/14651858.CD009684.pub2. Cochrane Database Syst Rev. 2017. PMID: 28836659 Free PMC article. Review.
Adverse events were only reported in participants from the zonisamide group, making it possible that they were aware of treatment group assignment. ...The most common AEs, experienced with zonisamide treatment, were headache, nausea, fatigue, sleepiness, and diarrho …
Adverse events were only reported in participants from the zonisamide group, making it possible that they were aware of treatment gro …
Introduction to zonisamide.
Baulac M. Baulac M. Epilepsy Res. 2006 Feb;68 Suppl 2:S3-9. doi: 10.1016/j.eplepsyres.2005.11.004. Epub 2006 Jan 18. Epilepsy Res. 2006. PMID: 16413170 Review.
A substantial body of clinical experience has accumulated over a 14-year period, allowing the properties and pharmacologic/clinical profiles of zonisamide to be clearly defined. Zonisamide is structurally distinct from other AEDs and has multiple and complementary m …
A substantial body of clinical experience has accumulated over a 14-year period, allowing the properties and pharmacologic/clinical profiles …
Zonisamide for neuropathic pain in adults.
Moore RA, Wiffen PJ, Derry S, Lunn MP. Moore RA, et al. Cochrane Database Syst Rev. 2015 Jan 22;1(1):CD011241. doi: 10.1002/14651858.CD011241.pub2. Cochrane Database Syst Rev. 2015. PMID: 25879104 Free PMC article. Review.
MAIN RESULTS: We included a single study treating 25 participants (13 zonisamide, 12 placebo) with painful diabetic neuropathy over 12 weeks. ...The small size of the study and potential major bias due to a high proportion of early study withdrawals with zonisamide
MAIN RESULTS: We included a single study treating 25 participants (13 zonisamide, 12 placebo) with painful diabetic neuropathy over 1 …
The effect of zonisamide on memory processes - A preclinical study.
Krupa-Burtnik A, Zwierzyńska E, Pietrzak B. Krupa-Burtnik A, et al. Epilepsy Behav. 2020 Jan;102:106659. doi: 10.1016/j.yebeh.2019.106659. Epub 2019 Nov 19. Epilepsy Behav. 2020. PMID: 31756621 Free article.
OBJECTIVE: Zonisamide is an antiepileptic drug with a perspective of a broader use. Although it is regarded as a relatively safe drug, zonisamide might cause disorders of the central nervous system. The study assessed the influence of zonisamide on spatial an …
OBJECTIVE: Zonisamide is an antiepileptic drug with a perspective of a broader use. Although it is regarded as a relatively safe drug …
Zonisamide-induced Choroidal Effusion: A Case Report.
Baradad Jurjo MC, Sanz Moreno S, Moix Gil E, Lillo Sopena J, Caminal Mitjana JM. Baradad Jurjo MC, et al. J Glaucoma. 2020 Sep;29(9):e100-e102. doi: 10.1097/IJG.0000000000001596. J Glaucoma. 2020. PMID: 32649452
PURPOSE: To describe a case of zonisamide-induced bilateral choroidal effusion. CASE REPORT: A 72-year-old woman presented with a 4-day history of bilateral blurred vision 9 days after initiating oral zonisamide for essential tremor. ...CONCLUSION: Zonisamide
PURPOSE: To describe a case of zonisamide-induced bilateral choroidal effusion. CASE REPORT: A 72-year-old woman presented with a 4-d …
Zonisamide: its pharmacology, efficacy and safety in clinical trials.
Brodie MJ, Ben-Menachem E, Chouette I, Giorgi L. Brodie MJ, et al. Acta Neurol Scand Suppl. 2012;(194):19-28. doi: 10.1111/ane.12016. Acta Neurol Scand Suppl. 2012. PMID: 23106522 Review.
In all four trials, zonisamide 300-600 mg/day resulted in significant reductions in median total seizure rates vs placebo, and zonisamide was generally well tolerated; the most frequently reported adverse events being somnolence, dizziness and anorexia/weight loss. …
In all four trials, zonisamide 300-600 mg/day resulted in significant reductions in median total seizure rates vs placebo, and zon
1,511 results